Clinical Significance Of Intraperitoneal Chemotherapy In The Treatment Of Epithelial Ovarian Cancer

Objective:To explore the application value of intravenous chemotherapy combined with intraperitoneal chemotherapy in patients with epithelial ovarian cancer,and compare the therapeutic effects of cisplatin intraperitoneal chemotherapy and carboplatin intraperitoneal chemotherapy.Methods:Collected from January 2010 to December 2015,patients with ovarian serous papillary adenocarcinoma in Shanxi Province Cancer Hospital,a total of 101 cases,according to whether they have received intraperitoneal chemotherapy,they are divided into intravenous chemotherapy combined with intraperitoneal chemotherapy In the study group and the control group of intravenous chemotherapy alone,61 of them were in the study group and 40 cases in the control group.Secondly,according to the different intraperitoneal chemotherapy drugs,the study group was divided into cisplatin intraperitoneal chemotherapy group and carboplatin intraperitoneal chemotherapy group.Comparison of age,FIGO staging,surgical methods,pathological results,Ca125,Ca199,HE4,CEA,etc.between groups before chemotherapy,comparison of gastrointestinal reactions,liver and kidney function effects,and bone marrow suppression between groups after chemotherapy,after follow-up Comparison of progression-free survival and overall survival between groups.Results:Before treatment,there was no statistical difference between the two groups based on the patient’s age,FIGO staging,surgical method,Ca125,HE4 and other general clinical data.After treatment,there were no significant differences between the study group combined with intraperitoneal chemotherapy and the control group with intravenous chemotherapy in terms of nausea,vomiting,gastrointestinal reaction,and bone marrow cell suppression.There were differences in liver and kidney damage,and there were differences in PFS between the two groups after treatment.(19.08VS14.82).The combined intraperitoneal chemotherapy group was divided into cisplatin group and carboplatin group based on the use of intraperitoneal chemotherapy drugs.The general clinical data,chemotherapeutic toxicity and survival analysis of the two groups were not statistically significant.Conclusion:This study compared postoperative chemotherapy regimens for patients with epithelial ovarian cancer.After statistical analysis,it was found that combined intraperitoneal chemotherapy did not increase the patients’ chemotherapy toxicity and3-year overall survival,but it had a longer PFS.Comparing the cisplatin intraperitoneal chemotherapy group and the carboplatin intraperitoneal chemotherapy group,although the carboplatin intraperitoneal chemotherapy group did not prolong the long-term survival of the patients,it did not increase the toxicity of the patients.Can be recommended for clinical use.